Other safety alerts
|
| |
| European Union: EMA reviewing safety of Uptravi for pulmonary arterial hypertension |
| |
The European Medicines Agency (EMA) is reviewing the safety of Uptravi (selexipag), following the deaths of 5 patients taking the medicine in France. Uptravi is used to treat pulmonary arterial hypertension (a life-threatening condition involving abnormally high blood pressure in the arteries of the lungs). Based on a preliminary review of available data, EMA advises that Uptravi may continue to be used, but use must be in line with the current prescribing information.
While the review is ongoing, EMA advises that doctors prescribing Uptravi carefully follow recommendations and precautions in the current prescribing information.
Patients taking Uptravi should follow their doctors’ instructions and can continue treatment with the medicine. Patients who have any questions about their treatment should speak to their doctor or pharmacist.
Please refer to the following website in EMA for details:
http://www.ema.europa.eu/../news_detail_002691.jsp&mid=WC0b01ac058004d5c1
In Hong Kong, there is no registered pharmaceutical product containing selexipag.
Ends/ Saturday, February 11, 2017
Issued at HKT 12:00
|
| |
|
